Aziyo Biologics - AZYO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.17
  • Forecasted Upside: 212.79 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$3.57
▼ -0.06 (-1.65%)

This chart shows the closing price for AZYO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aziyo Biologics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AZYO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AZYO

Analyst Price Target is $11.17
▲ +212.79% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Aziyo Biologics in the last 3 months. The average price target is $11.17, with a high forecast of $13.00 and a low forecast of $10.00. The average price target represents a 212.79% upside from the last price of $3.57.

This chart shows the closing price for AZYO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Aziyo Biologics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/14/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/12/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/11/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/11/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/9/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/7/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/6/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/6/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/16/2022Truist FinancialBoost TargetBuy$8.00 ➝ $10.00Low
11/15/2022Piper SandlerBoost TargetOverweight$9.00 ➝ $10.50Low
5/24/2022Cantor FitzgeraldReiterated RatingOverweightHigh
3/4/2022CowenLower TargetOutperform$15.00 ➝ $13.00High
11/11/2021Cantor FitzgeraldReiterated RatingOverweightLow
11/9/2021Piper SandlerLower TargetOverweight$14.00 ➝ $11.00High
11/2/2020Truist FinancialInitiated CoverageBuy ➝ Buy$20.00High
11/2/2020Piper SandlerInitiated CoverageOverweight$20.00High
11/2/2020CowenInitiated CoverageOutperform$20.00High
11/2/2020Cantor FitzgeraldInitiated CoverageOverweight$20.00High
(Data available from 12/7/2017 forward)

News Sentiment Rating

0.60 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/10/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/10/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/9/2022
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/8/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/8/2022
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/7/2022
  • 6 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
12/7/2022

Current Sentiment

  • 6 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Aziyo Biologics logo
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device. The company also provides cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. In addition, it offers Fiber VBM, ViBone, and OsteGro V that are human tissue-derived bone allografts designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. Further, the company provides contract manufacturing services for various products to corporate customers. It sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. The company was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
Read More

Today's Range

Now: $3.57
Low: $3.57
High: $3.57

50 Day Range

MA: $7.27
Low: $3.61
High: $8.62

52 Week Range

Now: $3.57
Low: $3.55
High: $9.01

Volume

6 shs

Average Volume

39,618 shs

Market Capitalization

$48.62 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Aziyo Biologics?

The following Wall Street sell-side analysts have issued stock ratings on Aziyo Biologics in the last twelve months: Cantor Fitzgerald, Cowen Inc, Piper Sandler, and Truist Financial Co..
View the latest analyst ratings for AZYO.

What is the current price target for Aziyo Biologics?

3 Wall Street analysts have set twelve-month price targets for Aziyo Biologics in the last year. Their average twelve-month price target is $11.17, suggesting a possible upside of 212.8%. Cowen Inc has the highest price target set, predicting AZYO will reach $13.00 in the next twelve months. Truist Financial Co. has the lowest price target set, forecasting a price of $10.00 for Aziyo Biologics in the next year.
View the latest price targets for AZYO.

What is the current consensus analyst rating for Aziyo Biologics?

Aziyo Biologics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AZYO will outperform the market and that investors should add to their positions of Aziyo Biologics.
View the latest ratings for AZYO.

What other companies compete with Aziyo Biologics?

How do I contact Aziyo Biologics' investor relations team?

The company's listed phone number is 240-247-1143 and its investor relations email address is [email protected] The official website for Aziyo Biologics is www.aziyobiologics.com. Learn More about contacing Aziyo Biologics investor relations.